537034-17-6

Basic information

• Product Name: BML-210
• Synonyms: N-PHENYL-N'-(2-AMINOPHENYL)HEXAMETHYLENEDIAMIDE;N-(2-AMINOPHENYL)-N'-PHENYL-OCTANEDIAMIDE;BML-210;CAY10433;N1-(2-aminophenyl)-N8-phenyl-octanediamide;BML-210(CAY10433)
• CAS NO: 537034-17-6
• Molecular Formula: C20H25N3O2
• Molecular Weight: 339.43
• Mol File: 537034-17-6.mol
• Article Data: 1

Chemical Properties

• Appearance: white to very faintly yellow/
• Storage Temp.: 2-8°C
• Solubility: DMSO: >20mg/mL
• Stability: Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months.
• CAS DataBase Reference: BML-210(CAS DataBase Reference)
• NIST Chemistry Reference: BML-210(537034-17-6)
• EPA Substance Registry System: BML-210(537034-17-6)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 537034-17-6(Hazardous Substances Data)

Usage

Description

Inhibition of histone deacetylase (HDAC) enzymes by compounds such as trichostatin A can have wide ranging effects in cancer, cell differentiation, and other aspects of gene expression regulation. BML-210 is a small molecule inhibitor of HDAC with an IC50 value of 30 μM when tested in HeLa cell nuclear extracts using 200 μM acetylated fluorometric substrate (substrate available in Cayman’s HDAC Activity and Inhibitor Screening Assay Kits - Item Nos. 10011563 and 10011564).

Uses

N1-(2-Aminophenyl)-N8-phenyloctanediamide is a histone deacetylase (HDAC) inhibitor, an anti-cancer target for breast cancer therapeutic intervention.

Definition

ChEBI: A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and 1,2-diaminobenzene.

Biochem/physiol Actions

BML-210 is a synthetic benzamide and is a potential tumor inhibitor. It is used as a therapeutic agent to treat promyelocytic leukemia. In human leukemia cell lines (NB4, HL-60, THP-1, and K562), BML-210 modulates histone deacetylase and promotes apoptosis. BML-210 favors frataxin expression in neurodegenerative disease Friedreich′s ataxia (FRDA). It interacts with myocyte enhancer factor-2 (MEF2) via hydrogen-bonding and prevents histone deacetylase 4 (HDAC4) binding.

References

1) Savickiene, et al. (2006), The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines; Eur. J. Pharmacol. 549 9 2) Herman, et al. (2006), Histone deacetylase inhibitors reverse gene silencing in Friedreich’s ataxia; Nat. Chem. Biol. 10 551

Upstream product

• 160777-08-2 7-oxo-7-(phenylamino)heptanoic acid 
• 95-54-5 1,2-diamino-benzene 

Relevant articles and documents

HISTONE DEACETYLASE INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISEASES

The invention provides HDAC inhibitors that may be used as therapeutics for the treatment of a neurodegenerative or neuromuscular condition. The invention provides compounds of formula I. The invention also provides pharmaceutical compositions and articles of manufacture that include these compounds, as well as methods of treating and methods of preventing or delaying the onset of a neurodegenerative or neuromuscular condition.